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0.25 m/sec) (p=NS).
Conclusion: Long-term combined HRT has no favorable effects on large artery compli-
ance in hypertensive postmenopausal women. In the same population, abnormal circa-
dian BP variability does not attenuate the estrogen-induced alterations in arterial
elasticity.
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Placebo Controlled Trial
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BACKGROUND: Estrogen deficit may lead to cardiac autonomic function imbalance in
the postmenopausal women that may potentially increase cardiovascular risk. The physi-
ological mechanism by which estrogen replacement therapy (ERT) regulates the auto-
nomic nervous system in postmenopausal women remains unclear.
METHODS: Thirty nine patients aged 45-65 years with a previous total hysterectomy and
amenorrhea for 1 year prior to the surgery were enrolled in this prospective, randomized
double-blind, placebo-controlled trial. Women with obesity, cardiovascular, neurological
or metabolic disease were excluded. Conjugated estrogens were administered at a dose
of 0.625 mg daily during 12 weeks in 19 patients (52.6± 7.1 years), and matched placebo
in 20 women (53.8± 5.4 years). Cardiopulmonary and arterial baroreceptor response
was determined after 3 months of treatment in both groups. Arterial baroreflex sensitivity
(BRS) was determined after the intravenous bolus administration of vasoactive sub-
stances (phenylephrine 150 mcg, sodium nitroprussiate,100 mcg). Cardiopulmonary
baroreflex response(CBR) was calculated using venous occlusion plethysmography by
determining forearm blood flow changes (FBF) and peripheral vascular resistance (PVR)
to –10mmHg lower-body negative pressure (LBNP). All measurements were performed
between 8am-12m. All signals were analyzed with the winCPRS software (Absolutely
Aliens, Finland).
RESULTS: A significant increase in BRS was found after 3 months of ERT compared
with placebo; Phenylephrin; 9.28 ±3.72 vs 15.93±10.22, p=0.09 and Nitroprussiate;
6.7±2.73 vs. 12.68±8.40, p<0.01. During LBNP a higher FBF (1.10±0.39 vs.
0.81±0.15,p<0.05) was associated with lower PVR (97.7±32.5 vs. 129.4±43.5, p<0.05) in
the group receiving ERT compared to the placebo group.
CONCLUSIONS: Short term ERT (3 months) may modulate cardiovascular autonomic
responses leading to reduced sympathetic activity (PVR) and improving cardiovagal
response by increasing arterial baroreflex sensitivity in postmenopausal women. (Col-
ciencias Grant: 6566-04-11788)
1160-170 Irbesartan Significantly Reduces C-Reactive Protein 
After One Month of Therapy in Unstable Angina
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Aguzzi, Sonia Iacovella, Giovanna Liuzzo, Filippo Crea, Institution of Cardiology. Catholic 
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Background: A growing body of evidence supports the patophysiological role of renin-
angiotensin-system (RAS) in the athero-trombotic process, in cardiac remodelling and in
apoptosis. Angiotensin II (AgII) blockade seems to be able to reduce the progression of
atherosclerotic lesion, through an anti-inflammatory mechanism. A reduction of coronary
events has also been observed in trials with these classes of drugs. Therefore we evalu-
ated whether Irbersartan (a selective AgII blocking agent) may modulate the inflamma-
tory response in unstable angina (UA). Methods: We studied 25 UA (Braunwald’s class
IIIB) patients (pts) without hypertension, diabetes, heart failure. Patients were treated
with full conventional anti-ischemic therapy (i.v. nitrates, aspirin, clopidogrel, β -blockade,
statins, low molecular weight-heparin) except Angiotensin Converting Enzyme-inhibitors
and/or AgII inhibitors. Pts were divided into two groups of treatment: group 1 receiving
Irbesartan (300 mg/die) on the top of conventional treatment and group 2 receiving con-
ventional treatment and placebo. Patients were discharged with aspirin, clopidigrel, β -
blocking agents plus Irbesartan (group 1) or placebo (group 2). In all patients we mea-
sured High Sensitivity-CRP levels (Dade-Behring) at Coronary Care Unit entry and after
1 and 3 months of follow up. Results: At entry, CRP levels (median and range) were sim-
ilar in group 1 and group 2 (3.1; 0.7-17.7 and 2.5; 1.1-21.9 mg/L). In group 1, CRP signif-
icantly decreased after 1 and 3 months of follow up, being respectively 1.2 mg/L; 0.16-
10.07 and 0.86; 0.58-4.17 mg/L (P=0.038 versus entry), whereas no changes were
observed in group 2 (2.25; 0.99-4.09 and 1.57;0.22-5.75 mg/L at 1 and 3 months respec-
tively). Conclusions: Our data demonstrate that Irbesartan has an in vivo antinflamma-
tory effects as shown by reduction of CRP levels in patients receiving full medical
therapy, including statins,and after only one month of treatment. Our data suggest a role
for AgII inhibitors in plaque stabilization and may help to explain the reduction of coronary
events in patients treated with AgII Inhibitors.
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Background: Ghrelin, a novel and key peptide of energy homeostasis, is associated with
the growth hormone – insulin-like growth factor (IGF)-I axis. Previous studies demon-
strated that IGF-I plays a role in pathogenesis of heart failure (HF), in which metabolic
abnormalities such as insulin resistance may be induced. Thus, the present study was
designed to investigate the role of insulin resistance and its relation with ghrelin and/or
IGF-I in patients with HF.
Methods: We studied 14 patients; seven healthy control subjects (M/F=4/3, age: 62±4
[mean±SD] years), and seven patients with acute HF (NYHA class IV), without diabetes
mellitus or obesity (M/F=5/2, age: 63±11 years). Insulin sensitivity was assessed at 1
week and 3-6 months following acute HF by the steady-state plasma glucose (SSPG)
method using a somatostatin derivative, octreotide acetate. Blood samples were col-
lected to measure the levels of ghrelin and IGF-I. Serum ghrelin level was measured by
newly developed enzyme immunoassay system.
Results: In comparison with the control (76±8 mg/dl), the SSPG level in HF patients was
significantly increased at 1 week (118±30 mg/dl, P<0.01), indicating insulin resistance.
However, at 3-6 months following acute HF, the SSPG level was restored to the control
level (80±21 mg/dl) with the significant increase in serum ghrelin (from 12±6 to 29±28
fmol/mL, P<0.05) and IGF-I levels (from 106±17 to 122±18 ng/mL, P<0.05). In patients
with HF, ghrelin level correlated inversely with insulin resistance (R=-0.625, P<0.01) and
positively with IGF-I level (R=0.675, P<0.01).
Conclusions: In patients with acute HF, insulin resistance is induced in association with
decreased ghrelin and IGF-I levels. The present findings suggest a potential interaction
between the ghrelin-IGF-I system and glucose metabolism by insulin, which may contrib-
ute to pathophysiology of HF.
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1161-171 Blood Pressure Response to Strength Training Is 
Influenced by AGT (-20) Genotype in the Elderly
Anish Meerasahib, Ben Hurley, G. Martel, Steve Roth, University of Maryland,College 
Park, College Park, MD
Background: Several linkage and association studies support the role of the Angiotensi-
nogen (AGT) gene in the development of essential hypertension. The C/A polymorphism
at -20 position has been shown to modify the expression of AGT, which can elevate BP
by raising blood levels of AGT. The purpose of the investigation was to study the relation-
ship of AGT (-20) genotype with resting BP response to Strength Training (ST) in middle-
aged to older adults.
Methods: Fifty-five sedentary, healthy men and women who were homozygous for ade-
nine allele (A/A, n=37, 21 men & 16 women) or heterozygous (A/C, n=18, 11 men & 7
women) at AGT gene locus were enrolled in the study. All subjects went through three to
six months of ST done 3 days per week using Keiser air-powered variable resistance
exercise machines, each session lasting for approximately 45 minutes. One-repetition
maximum (1RM) strength, Body Fat (%) and Fat Free Mass were measured before and
after the ST program. Resting Systolic and Diastolic BP were measured on six separate
occasions before and after ST for each subject. AGT genotyping was performed from
each subject's genomic DNA.
Results: Significant training induced reductions were noticed in systolic BPs of female
subjects, which dropped from 123.4 ± 11.3 mm Hg to 120.1 ± 11.4 mm Hg (P<0.05). The
male subjects dropped their diastolic BPs from 77.2 ± 7.9 mm Hg to 75.0 ± 7.1mm Hg
(P<0.05). When analyzed using ANCOVA, accounting for the genotype and the differ-
ences in pre-systolic BP between the two genotypes, the change in systolic BP was sig-
nificantly greater in AA genotype than AC/CC genotype. Systolic BP in AA genotype
dropped from 128.2 ± 2.0 mm Hg to 123.8 ± 1.6 mm Hg (P<0.05), while AC/CC genotype
dropped their systolic BP from 121.0 ± 2.5 mm Hg to 119.8 ± 3.2 mm Hg (P<0.05). When
controlled for the differences in pre-diastolic BP between the two genotypes, the change
in diastolic BP was not significantly different between the two genotypes.
Conclusion: AGT (-20) genotype influences resting blood pressure response to strength
training such that training reduces systolic BP in homozygotes to a more degree than that
in heterozygotes.
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Background Recent studies have shown that angiotensin II type 1 (AT1) receptor-medi-
ated Akt activation induced vascular smooth muscle cell (VSMC) dedifferentiation in vitro.
However, the critical signal transductions affecting the VSMC phenotype remain unclear
in vivo. We examined which signal transduction acting through the AT1 receptor could
regulate the VSMC phenotype in SHRSP in vivo. Methods and Results- Male stroke-
prone hypertensive rats (SHRSP) were randomized and treated for 6 weeks with a vehi-
cle (n=20), an AT1 receptor antagonist (E4177; 30 mg/kg/day, n=20), or an angiotensin-
converting enzyme (ACE) inhibitor (cilazapril; 10 mg/kg/day, n=20). Protein expressions
were analyzed by immunoblots, and NAD(P)H oxidase activity measured by lumines-
cence assay. Both drugs showed equipotent effects on blood pressure, aortic morphol-
ogy, collagen deposition, p38 mitogen-activated protein kinase and p42/44 extracellular
signal-regulated kinase expression in the aorta (P<0.05 vs. the vehicle group, respec-
